Mode
Text Size
Log in / Sign up

Vonoprazan reduces delayed bleeding risk in patients with gastric post-endoscopic submucosal dissection ulcersVonoprazan may reduce bleeding risk for patients with gastric ulcers

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider vonoprazan to reduce delayed bleeding risk after gastric ESD while maintaining comparable healing rates to PPIs.

This meta-analysis evaluated the efficacy and safety of vonoprazan compared to proton pump inhibitors (PPIs) in patients with gastric post-endoscopic submucosal dissection (ESD) ulcers. The study included a total of 1,136 patients to compare primary and secondary outcomes related to ulcer management.

The primary finding was a significant reduction in delayed bleeding for patients treated with vonoprazan (2.76%) compared to those treated with PPIs (5.76%), with a reported RR of 0.51 (95% CI 0.29-0.89; P=0.02). Secondary outcomes, including ulcer healing rates at 4 weeks and 8 weeks, as well as ulcer shrinkage rates at 4 weeks and 8 weeks, showed no statistically significant differences between the two treatment groups.

Adverse events were reported as less frequent with vonopoprazan. However, the authors note that the bleeding estimate is based on few events and should be interpreted cautiously. Clinically, vonoprazan may offer a safer alternative to PPIs for managing post-ESD ulcers while maintaining comparable healing efficacy. The limited number of events in the primary outcome suggests that while the trend is favorable, the magnitude of effect should be weighed against the small sample of events.

How this fits prior evidence

This meta-analysis addresses a gap in the management of gastric post-endoscopic submucosal dissection (ESD) ulcers. While prior coverage noted that proton pump inhibitor therapy is a first-line treatment for gastroesophageal reflux disease, this study specifically evaluates vonoprazan as a potential alternative to PPIs in the context of post-procedural gastric ulcers. The finding of reduced delayed bleeding (RR=0.51) suggests vonoprazan may offer a specific safety advantage in post-ESD scenarios compared to standard PPI therapy.

When patients undergo a procedure called endoscopic submucosal dissection (ESD) to treat stomach issues, they often develop gastric ulcers. Managing these ulcers is critical because they can lead to delayed bleeding, which poses a serious risk to the patient.

Researchers looked at data from 1,136 patients to compare a newer medication, vonoprazan, against standard proton pump inhibitors (PPIs). The results showed that patients taking vonoprazan had a lower rate of delayed bleeding (2.76%) compared to those taking PPIs (5.76%). Additionally, the study found that vonoprazan was associated with fewer adverse events overall.

While the bleeding rates were lower with vonoprazan, the medication performed similarly to standard treatments when it came to how quickly the ulcers healed or shrank at 4 and 8 weeks. Because the total number of bleeding events was small, experts suggest looking at these specific bleeding numbers with caution. Talk to a doctor to see if this treatment fits your specific needs.

What this means for you:
Vonoprazan may lower bleeding risks and side effects for gastric ulcers while healing them as well as standard drugs.

Common questions

Is vonoprazan safer than standard acid blockers?

The study found that vonoprazan was associated with fewer adverse events than standard proton pump inhibitors. However, because the total number of bleeding events was small, the specific estimate for bleeding risk should be interpreted with caution. You should talk to your doctor about which medication is safest for your specific situation.

Does vonoprazan heal ulcers faster than other drugs?

The study found no significant difference between vonoprazan and standard proton pump inhibitors when measuring how quickly ulcers healed or shrank at 4 weeks or 8 weeks. Both treatments performed similarly in terms of the physical size and healing rate of the ulcers.

How much did it reduce the risk of bleeding?

In the study of 1,136 patients, the rate of delayed bleeding was 2.76% for those taking vonoprazan compared to 5.76% for those taking standard proton pump inhibitors. While this shows a lower rate for vonoprazan, the small number of total events means these results should be viewed carefully.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
BackgroundDelayed bleeding and artificial-ulcer healing are important clinical concerns after gastric endoscopic submucosal dissection (ESD). Vonoprazan rapidly suppresses gastric acid, but its efficacy relative to proton pump inhibitors (PPIs) remains uncertain.MethodsWe searched seven databases from inception to May 31, 2026. Randomized controlled trials (RCTs) comparing vonoprazan with PPIs after gastric ESD were included. Outcomes were pooled as relative risks (RRs) or mean differences (MDs), with 95% confidence intervals (CIs).ResultsEleven RCTs reported delayed-bleeding data for 1,136 participants (580 receiving vonoprazan and 556 receiving a PPI). Delayed bleeding occurred in 16/580 (2.76%) vs. 32/556 (5.76%) participants (RR = 0.51, 95% CI 0.29–0.89; P = 0.02). Nine trials contributed to the relative-effect estimate because two reported zero events in both arms; a risk-difference sensitivity analysis including all 11 trials supported the result. Ulcer healing rates did not differ at 4 weeks (RR = 0.93, 95% CI 0.65–1.33; P = 0.69) or 8 weeks (RR = 0.98, 95% CI 0.92–1.04; P = 0.49). Ulcer shrinkage rates also did not differ at 4 weeks (MD = −0.89, 95% CI −2.10 to 0.33; P = 0.15) or 8 weeks (MD = 0.45, 95% CI −0.27 to 1.16; P = 0.22). Adverse events were less frequent with vonoprazan (RR = 0.57, 95% CI 0.34–0.98; P = 0.04).ConclusionVonoprazan may reduce delayed bleeding and adverse events after gastric ESD while achieving ulcer healing and shrinkage comparable to PPIs; the bleeding estimate is based on few events and should be interpreted cautiously.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261424595, CRD420261424595.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.